224 related articles for article (PubMed ID: 33067577)
1. DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
Park CS; Lacorazza HD
Exp Mol Med; 2020 Oct; 52(10):1663-1672. PubMed ID: 33067577
[TBL] [Abstract][Full Text] [Related]
2. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Park CS; Lewis AH; Chen TJ; Bridges CS; Shen Y; Suppipat K; Puppi M; Tomolonis JA; Pang PD; Mistretta TA; Ma L; Green MR; Rau R; Lacorazza HD
Blood; 2019 Nov; 134(22):1960-1972. PubMed ID: 31515251
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
4. Stem cell maintenance and disease progression in chronic myeloid leukemia.
Ito T
Int J Hematol; 2013 Dec; 98(6):641-7. PubMed ID: 23550022
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.
Leo E; Mancini M; Aluigi M; Luatti S; Castagnetti F; Testoni N; Soverini S; Santucci MA; Martinelli G
PLoS One; 2013; 8(12):e81425. PubMed ID: 24339928
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
8. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
9. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
10. Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.
Holm F; Hellqvist E; Mason CN; Ali SA; Delos-Santos N; Barrett CL; Chun HJ; Minden MD; Moore RA; Marra MA; Runza V; Frazer KA; Sadarangani A; Jamieson CH
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15444-9. PubMed ID: 26621726
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
Mancini M; Castagnetti F; Soverini S; Leo E; De Benedittis C; Gugliotta G; Rosti G; Bavaro L; De Santis S; Monaldi C; Martelli M; Santucci MA; Cavo M; Martinelli G
J Cell Biochem; 2017 Nov; 118(11):3968-3975. PubMed ID: 28401599
[TBL] [Abstract][Full Text] [Related]
14. New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.
Stefanachi A; Leonetti F; Nicolotti O; Catto M; Pisani L; Cellamare S; Altomare C; Carotti A
Curr Cancer Drug Targets; 2012 Jun; 12(5):571-96. PubMed ID: 22414010
[TBL] [Abstract][Full Text] [Related]
15. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA
Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
[TBL] [Abstract][Full Text] [Related]
16. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
17. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
[TBL] [Abstract][Full Text] [Related]
18. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Ras-mediated signaling pathways in CML stem cells.
Bertacchini J; Ketabchi N; Mediani L; Capitani S; Marmiroli S; Saki N
Cell Oncol (Dordr); 2015 Dec; 38(6):407-18. PubMed ID: 26458816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
